Omega-3 Marketers Back Down On Comparisons To Amarin's Vascepa

Coromega Health and Omax will issue press releases explaining that the Amarin study each firm noted in previous releases was not relevant to omega-3 supplements. Releases subject to publication within three days of each settlement's finalization include six mentions of Amarin's Rx prescription triglyceride-lowering fish oil, Vascepa.

Finger Pointing_184348979_1200.jpg

The two omega-3 dietary supplement marketers Amarin Corp. PLC targeted in nearly identical false advertising complaints after they said their products provide cardiovascular health benefits similar to Amarin's Rx fish oil agree to publish nearly identical corrections.

On another litigation front, Amarin recently stumbled in its attempt to compel the International Trade Commission to block imports of...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Business

More from Wellness